Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma
September 30th 2023The addition of venetoclax to carfilzomib and dexamethasone increased response rates compared with carfilzomib plus dexamethasone alone in patients with t(11:14)-positive relapsed/refractory multiple myeloma.
Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features
September 30th 2023Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.
CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance in Multiple Myeloma
September 29th 2023The EZH2 inhibitor tazemetostat may mimic the role of the KDM6A gene in upregulating CD38 and CD48 expression, suggesting that this agent could restore responses to daratumamab in patients with multiple myeloma, according to a presentation at the 20th International Myeloma Society Annual Meeting.
IberVd Elicits Durable Responses in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
The combination of iberdomide plus bortezomib and dexamethasone produced deep responses with a manageable toxicity profile in patients with transplant-ineligible, newly diagnosed multiple myeloma, according to data from the phase 1/2 CC-220-MM-001 trial presented at the 2023 International Myeloma Society Annual Meeting.
Although quadruplet combination regimens featuring daratumumab demonstrated consistent efficacy in the treatment of patients with newly diagnosed multiple myeloma, certain prognostic factors were associated with early relapse, according to data from a retrospective analysis presented at the 2023 International Myeloma Society Annual Meeting.
Teclistamab Delivers Comparable Efficacy Between Real-World and MajesTEC-1 Myeloma Populations
September 29th 2023Treatment with teclistamab-cqyv in real-world patients with relapsed/refractory multiple myeloma elicited similar efficacy results and a comparable safety profile to findings from the phase 1/2 Majes-TEC-1 trial.
Daratumumab Plus KRd With Tandem Transplant Sustains Efficacy in High-Risk, Newly Diagnosed Myeloma
September 29th 2023Induction daratumumab, carfilzomib, lenalidomide, and dexamethasone followed by consolidation double transplant sustained efficacy and safety in patients with high-risk, newly diagnosed multiple myeloma.
PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma
Treatment with the combination of pomalidomide, bortezomib, and dexamethasone conferred a small, statistically nonsignificant overall survival benefit compared with bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Physical Activity Improves Performance, Frailty Scores, and PROs in Multiple Myeloma
Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores in patients with multiple myeloma receiving systemic treatment.
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma
Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.
Biallelic Deletion of TNFRSF17 Associated With Resistance to BCMA-Targeting Therapies In Myeloma
Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.
Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma
August 28th 2022High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.